MariTide vs Tirzepatide
Written by Aaron CuhaReviewed Sep 2026
The short answer
A once a month antibody and peptide combination in large final stage trials, against the approved once weekly drug that hits two switches. The first lost up to 20 percent of weight at 52 weeks in its early trial. The second lost about 21 percent at 72 weeks in SURMOUNT-1.
- MariTide people
- 0
- MariTide nulls
- 0
- Tirzepatide people
- 22,802
- Tirzepatide nulls
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
Dose
Approved titration: 2.5, 5, 7.5, 10, 12.5 and 15 mg
2.5, 5, 7.5, 10, 12.5 and 15 mg
The approved tirzepatide ladder, in mg.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
MariTideMaridebart Cafraglutide (MariTide, AMG 133)
Amgen's once a month obesity shot. It turns one appetite signal on (GLP-1) and blocks another (GIP). People lost up to about 20 percent of their weight in a year in a mid-stage study.
Column B
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A once a week shot that works on two hunger and blood sugar signals, GIP and GLP-1. In studies it led to more weight loss and lower blood sugar than drugs that work on GLP-1 alone.
Side by side, on the facts we can check
| What we compare | MariTide | Tirzepatide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (in final-stage studies) | FDA-approved (Mounjaro for type 2 diabetes and, from August 2026, to lower the risk of major heart and blood vessel problems in people with type 2 diabetes; Zepbound for weight management and sleep apnea) |
| Half-life | Weeks (monthly dosing) | ~5 days |
| Molecular weight | About 145 kDa: the maridebart antibody component is 144,765 Da (KEGG) and carries two conjugated GLP-1 peptide analogs | 4,813.5 Da |
| How it works | One part turns on the GLP-1 signal, which cuts appetite. The other part blocks the GIP signal. The drug is joined to an antibody, so one shot lasts a month. | It switches on two receptors at once, GIP and GLP-1. Both answer gut hormones after a meal. Together they make the body release insulin when blood sugar is high, hold back glucagon, slow how fast the stomach empties and turn down hunger. The GIP part is thought to add its own effect on how the body handles sugar and fat. |
| Studies in people | 2 | 11 |
| Evidence | Limited: 1 completed trial, none stating how many people | Strong: 9 completed trials, 22,802 people given it |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between MariTide and Tirzepatide?
MariTide: Amgen's once a month obesity shot. It turns one appetite signal on (GLP-1) and blocks another (GIP). People lost up to about 20 percent of their weight in a year in a mid-stage study. Tirzepatide: A once a week shot that works on two hunger and blood sugar signals, GIP and GLP-1. In studies it led to more weight loss and lower blood sugar than drugs that work on GLP-1 alone.
Which has stronger research evidence, MariTide or Tirzepatide?
Each compound gets a band worked out from facts we counted, with the math shown. MariTide is Limited (1 completed trial, none stating how many people). Tirzepatide is Strong (9 completed trials, 22,802 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are MariTide and Tirzepatide FDA-approved?
MariTide: Investigational (in final-stage studies). Tirzepatide: FDA-approved (Mounjaro for type 2 diabetes and, from August 2026, to lower the risk of major heart and blood vessel problems in people with type 2 diabetes; Zepbound for weight management and sleep apnea).
Related posts
Blog articles that cover MariTide or Tirzepatide, newest first.
- Dispatch / Sep 27, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 27, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 27, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 27, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.